SECURE SIGNED
Secondary prEvention of CardiovascUlaR disease in the Elderly trial
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0SECURE project word cloud
Explore the words cloud of the SECURE project. It provides you a very rough idea of what is the project "SECURE" about.
Project "SECURE" data sheet
The following table provides information about the project.
| Coordinator |
CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.)
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | http://www.secure-h2020.eu/ |
| Total cost | 6˙898˙301 € |
| EC max contribution | 5˙998˙786 € (87%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-PHC-2014-two-stage |
| Funding Scheme | RIA |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-05-01 to 2021-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CENTRO NACIONAL DE INVESTIGACIONESCARDIOVASCULARES CARLOS III (F.S.P.) | ES (MADRID) | coordinator | 1˙465˙972.00 |
| 2 | CHARITE - UNIVERSITAETSMEDIZIN BERLIN | DE (BERLIN) | participant | 1˙096˙546.00 |
| 3 | ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | IT (MILANO) | participant | 1˙034˙362.00 |
| 4 | SERVICIO MADRILENO DE SALUD | ES (MADRID) | participant | 794˙166.00 |
| 5 | ARTTIC | FR (PARIS) | participant | 391˙512.00 |
| 6 | FERRER INTERNATIONAL | ES (BARCELONA) | participant | 263˙574.00 |
| 7 | CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCON | FR (BESANCON CEDEX) | participant | 232˙609.00 |
| 8 | VSEOBECNA FAKULTNI NEMOCNICE V PRAZE | CZ (PRAHA 2) | participant | 219˙883.00 |
| 9 | UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU | PL (WROCLAW) | participant | 211˙251.00 |
| 10 | SEMMELWEIS EGYETEM | HU (BUDAPEST) | participant | 184˙650.00 |
| 11 | LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER | UK (LONDON) | participant | 104˙258.00 |
Map
Project objective
While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population (≥ 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.
Deliverables
| SECURE poster | Websites, patent fillings, videos etc. | 2020-04-01 17:10:11 |
| Project leaflet | Websites, patent fillings, videos etc. | 2020-04-01 17:10:11 |
| Detailed dissemination plan | Documents, reports | 2020-04-01 17:10:11 |
| Public website | Websites, patent fillings, videos etc. | 2020-04-01 17:10:11 |
Take a look to the deliverables list in detail: detailed list of SECURE deliverables.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2018 |
Borja Ibañez, José M Castellano, Valentin Fuster Polypill strategy at the heart of cardiovascular secondary prevention published pages: 9-10, ISSN: 1355-6037, DOI: 10.1136/heartjnl-2018-313464 |
Heart 105/1 | 2020-04-01 |
| 2019 |
Jose M. Castellano, Juan Verdejo, Salvador Ocampo, Marco Martinez Rios, Enrique Gómez-Ãlvarez, Gabriela Borrayo, Emilio Ruiz, Borja Ibáñez, Valentin Fuster, Misael Arroyo, Maria Teresa Colosia, Juan E. Becerril, Roberto Vázquez, Elias Rodriguez, Alejandro Rodriguez, Rafael Márquez, Enrique Gomez, Juan M. González, Jose L. Ubiarco, Jose F. Barrera, Bertha Vitela, Laura A. Aranda, VÃctor Pe Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study published pages: 31-40, ISSN: 0188-4409, DOI: 10.1016/j.arcmed.2019.04.001 |
Archives of Medical Research 50/1 | 2020-04-01 |
| 2017 |
Ruth Webster, Jose M Castellano, Oyere K Onuma Putting polypills into practice: challenges and lessons learned published pages: 1066-1074, ISSN: 0140-6736, DOI: 10.1016/s0140-6736(17)30558-5 |
The Lancet 389/10073 | 2020-04-01 |
| 2017 |
José M Castellano, ValentÃn Fuster, Catriona Jennings, Eva Prescott, Héctor Bueno Role of the polypill for secondary prevention in ischaemic heart disease published pages: 44-51, ISSN: 2047-4873, DOI: 10.1177/2047487317707324 |
European Journal of Preventive Cardiology 24/3_suppl | 2020-04-01 |
| 2017 |
Mrs. Fiona Ecarnot, Prof. François Schiele La polypill à travers les résultats de l\'étude HOPE 3 published pages: 12-16, ISSN: 0761-5035, DOI: |
La Lettre du Cardiologue N°505 / May 2017 | 2020-04-01 |
| 2015 |
José M. Castellano, ValentÃn Fuster Polypill, el policomprimido cardiovascular: del concepto a la realidad en España published pages: 19-24, ISSN: 1131-3587, DOI: 10.1016/S1131-3587(16)30005-X |
Revista Española de CardiologÃa Suplementos 15 | 2020-04-01 |
| 2015 |
Juan Tamargo, José M. Castellano, ValentÃn Fuster The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention published pages: S15-S23, ISSN: 0167-5273, DOI: 10.1016/S0167-5273(15)31028-7 |
International Journal of Cardiology 201 | 2020-04-01 |
| 2015 |
José M. Castellano, Héctor Bueno, ValentÃn Fuster The cardiovascular polypill: clinical data and ongoing studies published pages: S8-S14, ISSN: 0167-5273, DOI: 10.1016/S0167-5273(15)31027-5 |
International Journal of Cardiology 201 | 2020-04-01 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SECURE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SECURE" are provided by the European Opendata Portal: CORDIS opendata.